- Home
- BLTE vs ACHC Comparison
BLTE vs ACHC Comparison
Compare BLTE & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- ACHC
- Stock Information
- Founded
- BLTE 2018
- ACHC 2005
- Country
- BLTE United States
- ACHC United States
- Employees
- BLTE N/A
- ACHC N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- ACHC Medical Specialities
- Sector
- BLTE Health Care
- ACHC Health Care
- Exchange
- BLTE Nasdaq
- ACHC Nasdaq
- Market Cap
- BLTE 2.1B
- ACHC 2.0B
- IPO Year
- BLTE 2022
- ACHC N/A
- Fundamental
- Price
- BLTE $60.48
- ACHC $21.56
- Analyst Decision
- BLTE Strong Buy
- ACHC Buy
- Analyst Count
- BLTE 4
- ACHC 9
- Target Price
- BLTE $96.67
- ACHC $47.94
- AVG Volume (30 Days)
- BLTE 32.1K
- ACHC 1.8M
- Earning Date
- BLTE 08-08-2025
- ACHC 07-30-2025
- Dividend Yield
- BLTE N/A
- ACHC N/A
- EPS Growth
- BLTE N/A
- ACHC N/A
- EPS
- BLTE N/A
- ACHC 2.04
- Revenue
- BLTE N/A
- ACHC $3,156,417,000.00
- Revenue This Year
- BLTE N/A
- ACHC $7.83
- Revenue Next Year
- BLTE N/A
- ACHC $8.56
- P/E Ratio
- BLTE N/A
- ACHC $10.57
- Revenue Growth
- BLTE N/A
- ACHC 5.48
- 52 Week Low
- BLTE $43.70
- ACHC $20.36
- 52 Week High
- BLTE $86.53
- ACHC $82.41
- Technical
- Relative Strength Index (RSI)
- BLTE 46.26
- ACHC 41.33
- Support Level
- BLTE $58.55
- ACHC $20.47
- Resistance Level
- BLTE $62.49
- ACHC $23.18
- Average True Range (ATR)
- BLTE 1.81
- ACHC 0.98
- MACD
- BLTE -0.40
- ACHC -0.03
- Stochastic Oscillator
- BLTE 26.19
- ACHC 38.93
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.